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Background: The aim of the present study was to conduct a cross-cultural adaptation (with translation into 
Brazilian Portuguese) and validation of the European Organization for Research and Treatment of Cancer—
Quality of Life Questionnaire—Bone Metastases-22 (EORTC QLQ-BM22). 
Methods: Ninety-five bone metastasis patients (31 men and 64 women, mean age 58.36±8.90 years) took 
part in the investigation. The translation guide of the EORTC was used to translate from English into 
Brazilian Portuguese and adapt the instrument culturally. The reliability and the face, content and construct 
validities were tested.
Results: Internal consistency was estimated using Cronbach’s alpha for the total score, pain and functional 
subscales of the EORTC QLQ-BM22 (0.93, 0.86, 0.90). Reliability was analyzed by Pearson’s correlation 
and intraclass correlation coefficients (ICCs). The correlations were higher than the recommended value of 
0.75, which indicated good test-retest reliability. Construct validity was demonstrated by correlation with 
the questionnaire medical outcome study questionnaire 36-Item Short Form Survey (SF-36). It showed 
significant correlation between the fields of QLQ-BM22 and the SF-36 (P≤0.001).
Conclusions: The EORTC QLQ-BM22 was translated into Brazilian Portuguese, was culturally adapted 
and was proven to be reliable, with face, content and construct validity.
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Introduction
Metastatic disease is the main cause of death among cancer 
patients. Bones are the third most common site of metastasis, 
after liver and lungs. Breast, prostate, lung thyroid and 
kidney tumors are the tumors that most frequently 
metastasize to bone. At the Department of Orthopedic 
Oncology of São Paulo Hospital, the incidence of bone 
metastases from breast cancers represents 45% of all cases, 
followed by prostate (12%) and lung cancer (9%) (1).
Skeletal-related events (SREs) due to bone metastases 
cause a variety of morbidities, including pain, spinal cord 
compression, pathologic fractures and hypercalcemia. 
Such events may cause significant debilitation and may 
have a negative impact on quality of life and functional 
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independence (2).
Current management of bone metastases is aimed 
primarily at reducing morbidity due to SREs to preserve or 
improve both quality of life and functional independence. 
Preventing SREs and improving survival are the goals of 
both current and future research (1).
Valid and reliable instruments are required to quantify 
the quality of life of patients with bone metastases. The 
European Organization for Research and Treatment 
of Cancer—Quality of Life Questionnaire—Bone 
Metastases-22 (EORTC QLQ-BM22), a 22-item module 
that was designed to measure symptoms, functions, 
psychosocial variables and expectations of patients with 
bone metastases. In Brazil, prior to the present study, there 
was no instrument that could evaluate the quality of life of 
cancer patients with bone metastases (3,4).
The aim of the present study was to translate the 
EORTC QLQ-BM22 into Brazilian Portuguese, to adapt 
the instrument culturally and to validate the newly adapted 
instrument.
Methods
This original, longitudinal, observational study was 
designed with no control group and was approved by the 
Ethics Committee of Universidade Federal de São Paulo, 
Brazil (CEP-UNIFESP/EPM 1649/11). Ninety-five 
bone metastasis patients (31 men and 64 women, mean 
age 58.36±8.90 years) took part in the investigation. All 
participants gave their written informed consent to take 
part in the study. The patients were recruited prospectively 
between August 2012 and August 2014.
They were eligible if they were over 21 years old, 
with histological confirmation of primary cancer and 
radiologic evidence of bone metastases (X-ray, CT, or 
bone scintigraphy). Exclusion criteria included inability to 
understand the questionnaire.
The original EORTC QLQ-BM22 module comprises 
22 questions that are organized into two scales: Symptom 
and Functional. Each of the scales has two subscales. The 
Symptom scale contains the painful sites (five questions) and 
painful characteristics (three questions) subscales, and the 
Functional scale contains the functional interference (eight 
questions) and psychosocial aspects (six questions) subscales.
After obtaining permission from the author, the English 
version of EORTC QLQ-BM22 was translated into 
Brazilian Portuguese by two independent expert translators. 
An additional two independent translators who were 
unfamiliar with the original, English EORTC QLQ-BM22 
version retranslated the Brazilian Portuguese translation 
into English. The translated versions were discussed 
and compared with the original version. The Brazilian 
Portuguese version of EORTC QLQ-BM22 was pilot-
tested in 15 Brazilian cancer patients with bone metastases. 
The patients understood all questions of the EORTC 
QLQ-BM22, reporting that all items were acceptable and 
understandable. No changes were made.
To test reliability, forty patients were evaluated three 
times, by two interviewers, using the Brazilian Portuguese 
version of EORTC QLQ-BM22. To assess the inter-rater 
reliability, the patients were evaluated twice by two distinct 
interviewers. Fifteen days after the first interview, the test-
retest reliability was assessed by repeating the EORTC 
QLQ-BM22 evaluation. Intraclass correlation coefficients 
(ICCs) and Pearson’s correlation coefficient were used to 
analyze inter-rater reliability and test-retest reliability. The 
internal consistency of the scale (module and scale) was 
evaluated using Cronbach’s alpha coefficient in all EORTC 
QLQ-BM22 evaluations.
Face and content validity were assessed by one 
multidisciplinary committee (consisting of a doctor, 
physiotherapist, nurse and psychologist). To assess the 
construct validity, 40 patients were evaluated by the 
EORTC QLQ-BM22 and the Brazilian version of the 
Short Form Health Survey [36-Item Short Form Survey 
(SF-36)]. To analyze construct validity, Pearson’s correlation 
coefficient was tested between the questionnaires. A 
probability level less than 0.05 was considered statistically 
significant. The analyses were conducted using the SPSS 
version 16.0 software.
Results
Patient demographics
A total of 95 patients were enrolled, with 64 (67.4%) 
female and 31 (32.6%) male, in whom the breast (n=50; 
53%), prostate (n=17, 18%) and lung (n=11, 12%) were 
the most common primary cancer sites and spine (n=42, 
27%), pelvis (n=28, 18%), and femur (n=28, 18%) were the 
most common bone metastasis site. The median age was 
58.36±8.90 years (Table 1).
Translation
After the translation process by two independent translators, 
two Portuguese versions of the EORTC QLQ-BM22 were 
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prepared and were then reviewed by a multidisciplinary 
committee that drafted a single version in Portuguese. 
This Portuguese version was retranslated into English by 
two independent translators, who created two Portuguese 
versions of the questionnaire. These two versions were 
analyzed and compared to the original version to discern 
possible differences or discrepancies in the translation 
process. At the end of this stage, the final version of the 
EORTC QLQ-BM22 was drafted in Portuguese.
Transcultural adaptation 
One patient (6.6%) did not understand the term “constant” 
in question number 6 (You had constant pain?), and one 
patient (6.6%) did not understand the term “intermittent” 
in question 7 (You had intermittent pain?). Because 
the proportion of patients affected was less than 10%, 
it was not necessary to modify these terms. Thus, the 
Portuguese measure was considered culturally equivalent 
to the English measure, and there was no need for any 
changes to the questionnaire. The average time taken to 
answer the questionnaire was 8 minutes, with a range of 5 
to 14 minutes. The degree of internal consistency of the 
questionnaire was measured in each of the three interviews. 
It was determined that the Cronbach’s alpha value was high 
in all three interviews, and these alpha values show that the 
questionnaire is fairly consistent (Table 2).
The accuracy of the EORTC QLQ-BM22 Brazilian 
Portuguese version was evaluated by Cronbach’s alpha 
analysis. The alpha value for the entire scale exceeded 0.8 
(Table 2). Only one items measures presented Cronbach’s 
alpha value less than 0.8 (painful sites =0.696). The others 
items measures exceeding 0.8 (painful characteristics =0.845; 
functional interference =0.938; psychosocial aspects =0.806).
We can conclude from these data that both the Pearson 
correlation and the intraclass correlation values are 
statistically significant and very high, showing that the first 
interview has excellent reliability and validity with the two 
additional interviews (Table 3).
Validity
We analyzed the results of the correlation between 
symptom QLQ-BM22 with the SF-36. This indicates the 
existence of a significant correlation between the symptom 
domain of the QLQ-BM22 and the areas of functioning, 
bodily pain, general health, vitality, and social aspects as 
well as the domains of limitation by emotional aspects and 
mental health from the SF-36 (P<0.05). Only the domain of 
limited by physical appearance showed no correlation with 
Table 1 Patients’ clinical and demographic data
Characteristics Overall n=95
Gender (%)
Female 64 (67.4%)
Male 31 (32.6%)
Age (SD) 58.36 (8.90)
Education (%)
Elementary 31 (33%)
High school 57 (60%)
University 7 (7%)
Cancer site (%)
Breast 50 (53%)
Prostate 17 (18%)
Lung 11 (12%)
Colon 5 (5%)
Uterus 4 (4%)
Lymphoma 3 (3%)
Kdney 2 (2%)
Bladder 1 (1%)
Stomach 1 (1%)
Bone metastase site (%)
Spine 42 (27%)
Pelvis 28 (18%)
Femur 28 (18%)
Ribs 19 (12%)
Humerus 14 (9%)
Clavicle 15 (10%)
Scapula 10 (6%)
Skull 1 (1%)
Table 2 Cronbach’s alpha value per interview 
Interview Cronbach’s alpha value
1 0.935
2 0.936
3 0.937
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the symptom domain of the QLQ-BM22 (Table 4).
Analysis of construct validity revealed moderate and 
strong correlations between the SF-36 coefficients and the 
EORTC QLQ-BM22 score (total and subscale).
Discussion
The incidence of SREs has been increasing, possibly due 
to the improvements in treatment of the primary site and 
treatment of disseminated cancer, thereby increasing the 
survival of these patients (5). 
Bone metastases cause various co-morbidities, including 
pain, pathologic fractures, hypercalcemia and spinal cord 
compression. These events have a negative impact on 
the quality of life and functional independence of cancer 
patients (6).
Currently, there are concerns not only about the 
results of the treatment or surgical intervention but also 
about the functional and emotional impact on the quality 
of life. The challenge for researchers is to quantify the 
subjective character data and determine what issues 
should be addressed. Generally, measurement tools are 
created originally in English, so it is necessary to complete 
the translation process and then evaluate the measure’s 
properties in a specific cultural context (7,8). 
Each country has its own customs, beliefs, behaviors and 
habits that directly reflect its culture and differences. To 
translate a tool, we should aim to present the tool in easy-
to-understand language and simple, clear words that are 
appropriate to the culture, without losing the essence of the 
original version.
The choice of a tool for evaluation depends on a 
few factors. Initially, the tool must have credibility and 
comprehensiveness, accuracy and reproducibility. The 
tool should also be easy to apply and have acceptability 
among the interviewees and interviewers (9). Evaluation 
questionnaires must be reproducible over time and should 
thus produce the same or similar results in two or more 
administrations to the same patient if the patient’s medical 
condition did not change (10). None of patients in this 
study had any changes in their treatment or intervention 
Table 3 Correlation among the three interviews (overall n=40)
Scale
Pearson’s ICC’s
Coefficient P Coefficient P
BM22
Interview 2 0.988 <0.001 0.994 <0.001
Interview 3 0.987 <0.001 0.994 <0.001
Painful sites
Interview 2 0.981 <0.001 0.986 <0.001
Interview 3 0.981 <0.001 0.990 <0.001
Paintful characteristics
Interview 2 0.981 <0.001 0.990 <0.001
Interview 3 0.981 <0.001 0.990 <0.001
Funcional interference
Interview 2 0.962 <0.001 0.981 <0.001
Interview 3 0.974 <0.001 0.986 <0.001
Psychosocial aspect
Interview 2 0.985 <0.001 0.993 <0.001
Interview 3 0.982 <0.001 0.991 <0.001
ICC, intraclass correlation coefficient; BM22, Bone Metastases-22.
Table 4 Correlation between QLQ-BM22 and SF-36 scales
SF-36 scale
QLQ-BM22 
score
Funcional Pain
Physical functioning 0.675 0.665 −0.572
P <0.001 <0.001 <0.001
Physical role functioning 0.446 0.520 −0.209
P 0.004 <0.001 <0.001
Bodily pain 0.705 0.722 −0.534
P <0.001 <0.001 <0.001
General health 
perceptions
0.822 0.808 −0.688
P <0.001 <0.001 <0.001
Vatality 0.875 0.884 −0.557
P <0.001 <0.001 <0.001
Social role functioning 0.771 0.833 −0.557
P <0.001 <0.001 <0.001
Emotional role functioning 0.794 0.833 −0.560
P <0.001 <0.001 <0.001
Mental health 0.851 0.870 −0.674
P <0.001 <0.001 <0.001
QLQ-BM22, Quality of Life Questionnaire—Bone Metastases-22; 
SF-36, 36-Item Short Form Survey.
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during the research, thus justifying the great inter-rater 
agreement.
There are functional assessment for patients with 
musculoskeletal tumors: the Musculoskeletal Tumor Society 
Rating Scale (MSTS) measures the functional impairment of 
patients with musculoskeletal tumors submitted to member 
preservation surgery, and Toronto Extremity Salvage Score 
(TESS) evaluates physical disability, according to the 
report based on this same group of patients (11,12). TESS 
was translated into Brazilian Portuguese and validated in 
patients with osteosarcoma, and the MSTS was validated 
in patients with diagnoses of musculoskeletal tumors, 
osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. 
Although the two tools assess patients with musculoskeletal 
tumors, they are very specific, and it is thus not possible to 
use them to evaluate bone metastasis patients (13,14).
Among the cases of musculoskeletal cancer, bone 
metastasis is the most frequent complication, and it can 
lead to the presence of pain and loss of function, thereby 
worsening the quality of life of these patients. There 
was a need for a specific tool that aids in the clinical and 
therapeutic monitoring of these patients by evaluating 
the quality of life. This study sought to evaluate a tool 
that met this need and addressed issues related solely 
to the characteristic symptoms of patients with bone 
metastasis in a simple and objective way. The QLQ-
BM22 is an instrument available in the literature that has 
been translated and validated for use in Japan, Iran and 
Poland (4,15-18).
In the validation phase of the QLQ- BM22, it was 
observed that 68.2% of the patients had primary site as 
breast cancer, followed by prostate (11.5%) and lung (7.8%) 
cancer (4). By analyzing the characteristics of the sample 
according to the primary site of cancer, we found that breast 
(49.47%), prostate (21.05%) and lung (11.57%) were the 
most common primary sites of metastases, as reported in 
previous studies (1,19).
For a long time, assessments of a given intervention 
were performed using clinical criteria. Currently, there 
is a consensus on the need for standardized evaluation 
systems. There is also a need to compare results of different 
treatment methods in patients with the same problem and 
to analyze the effectiveness of a treatment modality with 
greater reliability.
Because of the high incidence of patients with bone 
metastases and the progress of treatment, the QLQ-BM22 
can help multidisciplinary professionals evaluate patients 
by following the evolution of symptoms and functioning. 
However, the tool can also be used to determine the effect 
of different treatments on a patient, so the best approach 
can be chosen to improve the patient’s quality of life and 
well-being (1,20).
Conclusions
The QLQ-BM22 was translated into Brazilian Portuguese, 
and it was culturally adapted and proved to be reproducible. 
The translated, culturally adapted tool was determined to 
have face, content and construct validity.
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